Gu HY - Search Results

1

Disruption of DNA-PKcs-mediated cGAS retention on damaged chromatin potentiates DNA damage-inducing agent-induced anti-multiple myeloma activity.

Zhang JN, Dong MM, Cao W, Chen HG, Gu HY, Feng YL, Zhang EF, He JS, Liu SC, Xie AY, Cai Z. Zhang JN, et al. Among authors: gu hy. Br J Cancer. 2024 Aug;131(3):430-443. doi: 10.1038/s41416-024-02742-3. Epub 2024 Jun 14. Br J Cancer. 2024. PMID: 38877108

2

The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.

Huang X, Gu H, Zhang E, Chen Q, Cao W, Yan H, Chen J, Yang L, Lv N, He J, Yi Q, Cai Z. Huang X, et al. Int J Cancer. 2020 Apr 1;146(7):1963-1978. doi: 10.1002/ijc.32615. Epub 2019 Aug 24. Int J Cancer. 2020. PMID: 31390487 Free PMC article.

3

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/β-Catenin Signaling Pathways.

Wu X, Liu Y, Zhang E, Chen J, Huang X, Yan H, Cao W, Qu J, Gu H, Xu R, He J, Cai Z. Wu X, et al. Oxid Med Cell Longev. 2020 Aug 15;2020:6096391. doi: 10.1155/2020/6096391. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32879652 Free PMC article.

4

Emerging agents and regimens for multiple myeloma.

Yang Y, Li Y, Gu H, Dong M, Cai Z. Yang Y, et al. J Hematol Oncol. 2020 Nov 9;13(1):150. doi: 10.1186/s13045-020-00980-5. J Hematol Oncol. 2020. PMID: 33168044 Free PMC article. Review.

5

RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways.

Qu J, Hou Y, Chen Q, Chen J, Li Y, Zhang E, Gu H, Xu R, Liu Y, Cao W, Zhang J, Cao L, He J, Cai Z. Qu J, et al. Oncogene. 2022 Jan;41(3):400-413. doi: 10.1038/s41388-021-02095-8. Epub 2021 Nov 10. Oncogene. 2022. PMID: 34759347 Free PMC article.

6

Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis.

Liu Y, Yan H, Gu H, Zhang E, He J, Cao W, Qu J, Xu R, Cao L, He D, Zhang J, Hou Y, Cai Z. Liu Y, et al. Oncoimmunology. 2022 Mar 31;11(1):2057837. doi: 10.1080/2162402X.2022.2057837. eCollection 2022. Oncoimmunology. 2022. PMID: 35371618 Free PMC article.

7

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression.

Cao L, Chen Q, Gu H, Li Y, Cao W, Liu Y, Qu J, Hou Y, Chen J, Zhang E, He J, Cai Z. Cao L, et al. Clin Epigenetics. 2022 Jul 7;14(1):84. doi: 10.1186/s13148-022-01306-7. Clin Epigenetics. 2022. PMID: 35799216 Free PMC article.

8

Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma.

Yan H, He D, Qu J, Liu Y, Xu R, Gu H, Chen J, Li Y, Zhang E, Zhao Y, He J, Cai Z. Yan H, et al. Cancer Immunol Immunother. 2023 Feb;72(2):327-338. doi: 10.1007/s00262-022-03241-1. Epub 2022 Jul 26. Cancer Immunol Immunother. 2023. PMID: 35881196 Free PMC article.

9

Calcium silicate/bortezomib combinatory therapy for multiple myeloma.

Cao L, Gu H, Zhang Z, Zhang E, Chang J, Cai Z. Cao L, et al. J Mater Chem B. 2023 Mar 1;11(9):1929-1939. doi: 10.1039/d2tb02009b. J Mater Chem B. 2023. PMID: 36744994

10

Metabolic reprogramming in macrophage responses.

Liu Y, Xu R, Gu H, Zhang E, Qu J, Cao W, Huang X, Yan H, He J, Cai Z. Liu Y, et al. Biomark Res. 2021 Jan 6;9(1):1. doi: 10.1186/s40364-020-00251-y. Biomark Res. 2021. PMID: 33407885 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters